Safety Concerns Sink sNDA for Amag’s Anemia Drug

Drug Industry Daily
A A
Amag Pharmaceuticals’ regulatory woes deepened Wednesday as its bid to seek a new indication for its flagship iron deficiency drug Feraheme was rejected by FDA reviewers.

To View This Article:

Login

Subscribe To Drug Industry Daily